Pharma News

(9th September, 2014; Business Wire India); In its endeavour to build awareness and consciousness Apollo  Hospitals in association with ISQua, JCI, NABH and many other institutions hosted the 4th International Congress on Patient Safety along with the 5th edition of International Conference on Transforming Healthcare with IT 2014 for the first time in the Eastern part of the country. The two day event took place on 5th and 6th of September, 2014 at ITC Sonar, Kolkata.

(7th September, 2014); India and Australia are exploring cooperation possibilities in preventive healthcare, trauma care, geriatric medicine, diabetes research and mental illnesses. This found iteration in the dialogue held between the visiting Prime Minister of Australia, Mr Tony Abbott, and the Union Health Minister, Dr Harsh Vardhan, on 5th Sept, Friday.

(5th September, 2014; Business Wire India); “India & Japan have a big opportunity of working together in the area of healthcare. Japan has achieved its goal of longevity and healthy life for all its citizens. This knowledge and technology will benefit India as well as the rest of the world. Shri Narendra Modi, Hon’ble Prime Minister of India, has already extended an open invitation to COME MAKE IN INDIA.  India will give Japan a huge consuming population, excellent human resources and a low cost base for manufacturing and exporting healthcare solutions to the world”, said Rajesh Srivastava, Chairman, Rockland Hospitals. He was speaking on the topic: Creating Healthcare Access for Cancer Treatment: Sharing Japanese Solutions, during a two days seminar titled FICCI- Heal-2014 on 1 & 2 Sept in Delhi.

(4th September, 2014); Florida Scientists from The Scripps Research Institute (TSRI) have considered chemical approach to convert diseased cells to be manufacturing site of a molecule which can treat muscular dystrophy. The promising research was published recently in the international chemistry journal Angewandte Chemie.

(3rd September, 2014); The news in July that HIV had returned in a Mississippi toddler after a two-year treatment-free remission dashed the hopes of clinicians, HIV researchers and the public at large tantalized by the possibility of a cure. But a new commentary by two leading HIV experts at Johns Hopkins argues that despite its disappointing outcome, the Mississippi case and two other recent HIV "rebounds" in adults, have yielded critical lessons about the virus' most perplexing - and maddening - feature: its ability to form cure-defying viral hideouts.

(3rd September, 2014); The new agent, an angiotensin receptor-neprilysin inhibitor (ARNI) known as LCZ696, has already been granted Fast Track status by the United States Food and Drug Administration (FDA) – a designation which can expedite the review of new medicines intended to treat serious or life-threatening conditions. And surprisingly, LCZ696 was superior to ACE-inhibitor, enalapril, on key endpoints in the largest heart failure study ever done.

Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin soon by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

(2nd September, 2014); Wockhardt Ltd’s New Drug Discovery program in Anti - Infective research received a major boost after two of its drugs, WCK 771 and WCK 2349, received the coveted Qualified Infectious Disease Product (QIDP) status from the US FDA. This is the first instance of an Indian Pharmaceutical company receiving a QIDP status.

[adsense:336x280:8701650588]

(2nd September, 2014; Business Wire India); Five years on from the first breakthrough presentation of the pivotal RE-LY^® clinical trial of Pradaxa^® (dabigatran etexilate) for the prevention of stroke in non-valvular atrial fibrillation (NVAF), extensive clinical trial and real-world data support Pradaxa^® in various indications. Boehringer Ingelheim continues to grow the evidence base for Pradaxa^® to improve care for patients at risk of blood clots and today announces the initiation of Phase III of the GLORIA™-AF registry program in North America and in Europe. During this final phase of the registry program, data on the overall safety and effectiveness of antithrombotic treatments will be collected.